Drugs / Safingol
Safingol
also known as
C18-L-threo-sphinganine · l-threo-dihydrosphingosine · NSC-714503 · Safingol hcl · SAFINGOL HYDROCHLORIDE · SPC-100270 · SPC-100271 · Threo-dihydrosphingosine,l-
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01553071 | Nov 2016 → Dec 2020 | cancer | South Plains Oncology Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT00084812 | Mar 2004 → Feb 2009 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | safingol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00084812 ↗ |
| Known as | C18-L-threo-sphinganine | “C18-L-threo-sphinganine (safingol, an anti-neoplastic in phase I trials)” PMID 30836314 ↗ Feb 2019 |
| Known as | l-threo-dihydrosphingosine | “Safingol, (l-threo-dihydrosphingosine) is a putative inhibitor of SphK.” PMID 21257722 ↗ Jan 2011 |
| Known as | NSC-714503 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1442934 ↗ |
| Known as | Safingol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1442934 ↗ |
| Known as | SAFINGOL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1442934 ↗ |
| Known as | SPC-100270 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1442934 ↗ |
| Known as | SPC-100271 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1442934 ↗ |
| Known as | Threo-dihydrosphingosine,l- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1442934 ↗ |
| Action | Inhibit | “Safingol, (l-threo-dihydrosphingosine) is a putative inhibitor of SphK.” PMID 21257722 ↗ Jan 2011 |
| Modality | Small molecule | “Safingol, a stereochemical-variant dihydroceramide precursor” NCT01553071 ↗ |
| Route | Intravenous | “Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1.” NCT00084812 ↗ |